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Abstract
Recent advances in complementary diagnostic exams have helped to clarify stroke etiology, not only by helping to confirm 
established stroke causes but also by unveiling new possible stroke mechanisms. Etiological investigation for cardioembolic 
stroke has benefited in the last years from information provided by studies analysing serum biomarkers, heart rhythm moni-
toring and imaging methods like cardiovascular magnetic resonance (CMR) imaging. CMR has been particularly important 
for the characterization of possible new cardioembolic stroke mechanisms including atrial cardiomyopathy, silent myocardial 
infarction and cardiomyopathies.
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Introduction
The classification of ischaemic stroke subtypes used, in gen-
eral, the simple and reliable TOAST typology [1], which, 
however, leaves around a ¼ of the cases unclassified. More 
detailed systems of classification, such as the ASCOD [2], 
decrease this proportion of cryptogenic strokes, by attribut-
ing the cause of stroke to “minor” arterial or cardiac embolic 
sources [3]. ASCOD is unfortunately too complex to use in 
daily practice. A related difficulty is the operational defini-
tion of cryptogenic stroke. A review of 16 clinical practice 
guidelines and 7 consensus statements found that none of 
the reports provided guidance on the extent of investigation 
needed to classify a stroke as cryptogenic [4].
Stroke may be labelled unclassified in patients with mul-
tiple causes or those with incomplete or delayed investi-
gations. In the remaining strokes of unknown cause, most 
are embolic with an unknown source (ESUS) [5]. In some 
of these patients, paroxysmal atrial fibrillation (AF) or a 
“minor” cardiopathy will be identified. Carotid webs [6–8] 
and cancer are also other possible sources of ESUS.
Advances in vessel imaging have unveiled other poten-
tial causative mechanisms including non-stenotic carotid 
or vertebral atheroma, ostium or branch intracranial artery 
and aortic arch atheroma. In the NAVIGATE ESUS trial, 
involving 7213 patients ESUS patients, the 3 most prevalent 
potential sources of embolism were atrial cardiopathy (37%), 
left ventricular disease (36%), and arterial atherosclerosis 
(29%) [9], but 7.5% had cancer [10]. Among participants 
who had transesophageal echocardiography (TEE), 29% 
had aortic arch atheroma [11]. Among those with intracra-
nial arterial imaging, 16% had intracranial atherosclerosis 
[12], while 12.6% patients met the criteria for intracranial 
branch atheroma [13]. In other recent studies, between 23.6 
and 38.6% of ESUS patients had ipsilateral < 50% carotid 
plaques [14, 15]. Nonstenotic carotid plaques were signifi-
cantly more common on the side of the ischemic stroke [16]. 
They were also ipsilateral to the infarction in patients with 
ESUS, but not in patients with AF, supporting an underly-
ing atheroembolic mechanism in a subset of ESUS patients 
[17]. The identification and quantification by MRI of certain 
carotid plaque characteristics, including lipid-rich necrotic 
core, thin/ruptured fibrous cap, and intraplaque hemorrhage 
(IPH), may improve the prediction of future stroke among 
ESUS patients [18]. In a systematic review of 7 studies with 
354 ESUS patients, the prevalence of IPH ipsilateral to the 
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ischemic lesion was 25.8%. The odds of having IPH on the 
ipsilateral side versus the contralateral side was 6.92 [19].
The carotid web is another cause of cryptogenic stroke, 
particularly in younger patients without vascular risk fac-
tors [6–8, 20]. The web is a thin intraluminal filling defect 
along the posterior wall of the carotid bulb, on oblique sag-
ittal section of CT angiography (CTA), seen as a septum 
on axial CTA. Pathologically, it is an intimal fibromuscular 
dysplasia. The web causes flow stagnation and remote embo-
lization of fibrin-based clots. Carotid webs were found at a 
significantly higher frequency in patients with cryptogenic 
ischemic strokes compared to controls. Additionally, intrac-
ranial large vessel occlusions were more common in patients 
with symptomatic carotid webs, presenting with ipsilateral 
strokes [21].
These studies demonstrate the impact that recent advances 
in complementary diagnostic exams have had in helping to 
clarify stroke etiology. Not only by aiding to confirm stroke 
etiology but also by unveiling new possible stroke mecha-
nisms. Cardioembolic stroke investigation has benefited in 
the last years from information provided by studies analysing 
serum biomarkers, heart rhythm monitoring and imaging 
exams like cardiovascular magnetic resonance (CMR) imag-
ing [22, 23]. CMR has had a progressively more important 
role in the evaluation of patients suspected of having cardi-
oembolic stroke.
Cardiovascular magnetic resonance
CMR is an imaging technique that is complementary to 
other modalities such as echocardiography, cardiac CT and 
nuclear cardiology. This technique is the gold standard to 
study cardiac structure and function and is, therefore, key to 
evidence-based diagnostic and therapeutic decisions [24].
By assessing cardiovascular anatomy, myocardial struc-
ture and characterization, biventricular systolic function and 
flow, CMR can be used to study pathologies ranging from 
myocardial ischemia and viability to cardiomyopathies, as 
well as pericardial, valvular, congenital and vascular dis-
eases [25].
A number of protocol sequences are currently used for 
imaging acquisition. These require ECG synchronization. 
Conventional sequences are acquired during cardiac cycles 
with short breath-holding periods.
Bright-blood cine sequences provide an excellent con-
trast between blood, myocardium and vessels, allowing the 
assessment of heart volumes and biventricular function, 
with CMR being a reference method for these calculations. 
Myocardial tissue structure characterization may be obtained 
using sequences such as black-blood imaging T1-weighted, 
T2-weighted (for edema) and fat-saturation. By administer-
ing gadolinium, and using an inversion-recovery sequence, 
it is possible to obtain different patterns of late gadolinium 
enhancement (LGE-CMR) of the diseased myocardium 
and characterize clinical conditions, like ischemic heart 
disease and cardiomyopathies. Using a saturation-recovery 
sequence, myocardial perfusion may be assessed during 
gadolinium infusion, after pharmacological stress. Other 
important applications include flow quantification (for val-
vular and vascular assessment) by phase-contrast sequences 
and MR angiography for vessel evaluation [25]. Recently, 
T1 and T2 mapping are available for myocardial charac-
terization in diseased states, namely for diagnosing diffuse 
fibrosis, inflammation, cardiac amyloid, Fabry disease and 
iron overload [26].
In some stroke patients, CMR performance may be chal-
lenging, but it is feasible, in both young and older patients, 
as long as they are able to hold their breath for some sec-
onds, stand still and understand the instructions for imaging 
acquisition. In exceptional cases, were further diagnosis is 
intended (e.g. tissue characterization) in non-cooperative 
patients, the use of sedation and of respiratory navigators, 
as needed, may ensure appropriate imaging. Although not 
routinely performed due to increased acquisition time, the 
use of respiratory navigators is feasible and available in most 
scanners.
[25]. Contraindications to CMR include claustrophobia, 
implanted ferromagnetic material like intraocular foreign 
bodies, cochlear implants, and usually non-conditional 
implantable electronic devices. Patients with severe renal 
failure with an eGFR below 30 mL/min/1.73m2 should not 
receive gadolinium due to the risk of nephrogenic systemic 
fibrosis [25]. Patients in critical care units should undergo 
CMR if the diagnostic information is crucial. In this case, 
appropriate stabilization should be performed, with full 
monitoring during the exam, which may be achieved with 
respiratory and hemodynamic support with MR compatible 
equipment [27].
Challenges of CMR in stroke assessment
CMR is probably not feasible, in most patients, in the acute 
phase of stroke where other techniques like echocardiogra-
phy or cardiac CTA have a more appropriate role for detect-
ing cardiac thrombi. CMR has long acquisition times and 
requires patients to stand still. In addition, patients need to 
be instructed to hold their breath. This may be difficult in 
stroke patients, especially in those with severe deficits (who 
might have a higher chance of having a cardiac source of 
embolism). CMR is complex and needs experienced physi-
cians and trained technicians. Although costs of CMR are 
variable in different countries, it is more costly than cardiac 
CTA. However, CMR has no radiation and provides a larger 
amount of information than cardiac CTA, namely on heart 
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function, flow and myocardial characterization that may be 
crucial for decision-making, thus being a valid option when 
safely and appropriately used.
CMR for the investigation of established 
causes of cardioembolic stroke
Echocardiography is the first-line exam to study a cardioem-
bolic etiology due to its availability and ability to be used at 
bedside. However, it is operator dependent and has acoustic 
window limitations and considerable measurement variabil-
ity. CMR may be complementary and have an incremental 
value to echocardiography. CMR does not have window 
restrictions, has high image resolution and reproducibility 
and has a unique capability to characterize tissue.
Cardiac CTA was recently suggested as an alternative 
technique for the workup of stroke of undetermined etiology, 
due to its high sensitivity and specificity for thrombus detec-
tion [28] in comparison with TEE as a reference standard 
[29]. Although cardiac CTA is a promising alternative to 
echocardiography it uses radiation and requires iodinated 
contrast. Acquisition of cardiac CTA images could poten-
tially be done in the acute stroke phase after the acquisi-
tion of brain CT. Delayed imaging may be diagnostic and 
needs a lower radiation dose. However, to ensure quality 
and diagnostic performance, ECG-gating and patient’s 
breath-holding is advised. The presence of arrhythmias and 
tachycardia may be a limitation that advanced scanners in 
the future may overcome. A recent meta-analysis that com-
pared cardiac CTA and TEE suggests a good accuracy to 
detect cardiac thrombi in ischemic stroke but advises cau-
tion since included studies were small, heterogeneous and 
in most studies both techniques were performed days apart 
from each other [30]. Also, cardiac CTA does not provide 
information concerning function or flow and is limited for 
tissue characterization.
CMR provides not only an accurate diagnosis of thrombi, 
flow velocities in the LAA and aorta atheroma characteriza-
tion but also detects and characterizes tumors, myocarditis, 
cardiomyopathies, atrial cardiomyopathy and silent myo-
cardial infarction which are potential sources of embolism 
(Table 1).
Atrial septal defect and patent foramen ovale
CMR is useful for the diagnosis of an atrial septal defect 
(ASD) when echocardiography is inconclusive and can help 
to quantify the size of the left-to-right shunt (Fig. 1). It is 
also useful for the diagnosis of a superior or inferior sinus 
venosus ASD, for multiple atrial septal defects and for the 
detection of associated anomalous pulmonary veins [31].
Table 1  Summary of current 
CMR role in stroke etiological 
investigation
TTE transthoracic echocardiogram, TEE transesophageal echocardiogram
a Additional tissue characterization
b Anatomic features
TTE TEE CMR Cardiac CTA 
Investigation of TOAST cardioembolic causes
 Atrial septal defect +/+++ +++ +++ +++
 PFO + +++ +  +/++ 
 LV thrombus + ++/+++ +++ +++
 LAA thrombus – +++ +++ +++
 Cardiac tumors + ++ +++a +++
 Endocarditis ++ +++ –/+ ++
 Aortic atheroma – ++/+ ++/+++a +++
New etiologic mechanisms
 Atrial cardiomyopathy – +/++ +++a +
 Silent myocardial infarction + + +++a ++
 Myocarditis and cardiomyopathy +/+++ +/++ +++a –/++b
Fig. 1  Still image from a cine MR sequence in four-chamber plane 
depicting an “ostium primum” defect (arrow)
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TEE often needing the performance of a Valsalva Maneu-
ver is the modality of choice for the diagnosis of PFO due to 
its high spatial and temporal resolution [32].
PFO may be detected with transthoracic echocardiogram 
(TTE) and agitated saline contrast but its sensitivity is lower 
than TEE, as it depends on the acoustic window and does not 
provide the anatomic characteristics of the left atrium or the 
quantification of microbubbles [33].
Detecting a PFO is challenging for CMR due to its usual 
small size and because frequently the right-to-left shunt 
develops after a Valsalva maneuver that occurs during few 
cardiac cycles. Since CMR cine acquisition needs several 
cycles’ for imaging, this may preclude the detection of tur-
bulence from the shunt. A first-pass perfusion CMR method 
with the evaluation of enhancement curves in the left and 
right atria has been able to successfully diagnose PFO but 
this technique needs to be validated [34]. The presence of a 
septal aneurysm, defined as septal bowing > 10 mm, is easily 
detected by cine CMR [35].
Cardiac thrombi
Thrombi are the most frequent cardiac masses. They tend to 
occur in areas of stasis, such as the left atrium and the left 
atrial appendage in association to atrial dilation and AF, or 
in the left ventricle in the presence of regional wall motion 
abnormalities or global ventricular dysfunction (Fig. 2).
Thrombi are diagnosed using T1- and T2-weighted black-
blood sequences, cine CMR and particularly by the absence 
of early or late gadolinium enhancement since they are avas-
cular which allows for them to be diagnosed against a differ-
ential diagnosis of other masses [36]. CMR is more accurate 
than echocardiography in detecting thrombi [37] and should 
be considered when echocardiography is inconclusive.
Baher et al. [38] conducted a prospective study of 106 
patients with ischemic stroke and transient ischemic attacks. 
After routine work-up, in 21% of patients CMR allowed a 
reclassification of cryptogenic causes into cardioembolic, 
mainly by improving the diagnosis of thrombi.
LV thrombi detected by LGE CMR but not by echocar-
diography are associated with a similar risk of embolism 
compared to that detected by both LGE CMR and echocar-
diography [39].
Tumors
Tumors can embolize, be arrhythmogenic or cause heart fail-
ure. CMR is a more valuable technique to diagnose cardiac 
tumors than echocardiography [40], due to its high tissue 
contrast, versatility in image planes, unique value for tis-
sue characterization, namely for water and fat identifica-
tion, which have specific patterns on T1 and T2-weighted 
techniques. Contrast-enhanced CMR can also evaluate 
tumor vascularity and fibrosis. Due to its large field of view, 
CMR can be used to detail the tumor´s relationship to other 
structures.
The majority of primary cardiac tumors are benign and 
myxomas are the most frequent type [41]. They are typically 
attached to the atrial septum, although they may occur in any 
cavity (Fig. 3a). They are often isointense on T1, hyperin-
tense on T2 and heterogeneous after contrast. Myxomas have 
a high embolization risk and surgical removal is indicated. 
Papillary fibroelastomas are small benign endocardial papil-
lomas affecting predominantly the cardiac valves (Fig. 3b). 
They are small and highly mobile masses, homogeneous and 
hypointense on cine images, isointense on T1 and hyperin-
tense on T2, and heterogeneous with contrast enhancement 
allowing for their differential diagnosis from vegetations. 
Clinically, fibroelastomas can be asymptomatic or associ-
ated with systemic embolization [41]. Lipomas are benign 
tumors that often arise from the epicardial surface. They 
are characterized by high intensity on T1 that is suppressed 
by fat saturation pulses. Other primary tumors like fibro-
mas or rhabdomyomas are intramural and have no embolic 
potential.
Primary malignant tumors are rare, more frequently sar-
comas or less often lymphomas, while metastatic tumors 
are 20–40 × more frequent [41]. Malignant tumors may be 
intramural but often protrude into the cardiac cavities and 
may embolize. Characteristically, these tumors have irregu-
lar contours and are infiltrative, heterogeneous in signal and 
on contrast-enhancement.
Infectious endocarditis
Cardioembolic stroke occurs in up to 35% of patients with 
infective endocarditis [42]. Very mobile vegetations that 
Fig. 2  Still image from a cine MR sequence in three-chamber plane 
showing a thrombus in the apex (arrow)
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are > 10 mm have a higher embolization risk [43]. CMR 
is not a first-line method for detecting valvular vegetations 
because it has limited spatial resolution for small mobile 
structures. Transesphageal echocardiography is the refer-
ence method for the diagnosis of infective endocarditis, 
complemented by cardiac CT and 18F-FDG PET-CT [43] 
in some cases.
CMR may be useful for diagnosing perivalvular compli-
cations in IE patients, such as perivalvular abscesses and 
inflammatory processes involving the myocardium [44]. 
Also, valve insufficiency severity and its hemodynamic 
significance can be assessed by CMR.
Aortic atheroma and other conditions
Atheroma plaques that are more than 4 mm in size, ulcer-
ated atheroma plaques, and atheroma plaques with mobile 
components considered as complex lesions, are associated 
with a fourfold risk of thromboembolism in comparison 
with plaques without complex features [45].
TEE is the reference method to study aortic atheroma 
located in the arch and in the proximal descending aorta. 
Black-blood CMR sequences have shown good correlation 
with TEE [46]. CMR has the advantage of an unrestricted 
view field and the potential of diagnosing mural thrombi. 
High-resolution scanners have the potential to diagnose 
intraplaque hemorrhage and evaluate lipid content. How-
ever, calcification is not well detected by CMR. Contrast-
enhanced MR angiography provides images of protruding 
complex plaques with diagnostic power [47].
CMR has been used to evaluate carotid atherosclero-
sis. In a study using histological validation obtained from 
carotid endarterectomy specimens, CMR was able to char-
acterize lipid-rich necrotic cores, fibrous caps, intraplaque 
haemorrhage, calcification, and inflammation [48].
CMR for investigation of cryptogenic stroke
CMR has helped in the last years to identify possible 
stroke causes that are not part of standard ischemic stroke 
etiological classifications. These situations include atrial 
cardiomyopathy, cardiomyopathies and silent myocardial 
infarctions.
Atrial cardiomyopathy
Recent studies suggest that AF is the final point of a 
disease characterized by morphological and structural 
changes in the atria. There is increasing evidence that a 
structural atrial condition defined as fibrotic atrial cardio-
myopathy can precede the occurrence of AF [49]. These 
changes could increase the probability of thrombi forma-
tion. A decrease in left atrial ejection fraction could induce 
stasis, and an increase in atrial fibrosis could lead to both 
stasis and endocardium changes that favor thromboembo-
lism [46]. CMR with late gadolinium enhancement can 
identify atrial fibrosis. Fonseca et al. compared the left 
atrium (LA) of patients with different ischemic stroke 
causes using CMR [50]. Patients with structural changes 
on echocardiography considered as causal for stroke in 
the TOAST classification were excluded. One hundred 
and eleven patients were evaluated. A 3Tesla CMR was 
performed. Patients with an undetermined cause had a 
higher percentage of LA fibrosis (p = 0.03) than patients 
with other stroke causes and lower, although not statisti-
cally significant, values of LA ejection fraction. Patients 
with atrial fibrillation and undetermined stroke causes 
showed a similar value of atrial fibrosis. Similar results 
were found by Tandon et al., in a study using CMR, odds 
ratios of ESUS per quartile of fibrosis were 3.17 (95% CI 
Fig. 3  a Still image from a cine 
MR sequence in four-chamber 
plane showing a myxoma 
attached to the interatrial 
septum (arrow), b left ventricle 
short-axis T1W image showing 
a fibroelastoma attached to the 
mitral valve (arrow)
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1.05–9.52, p = 0.041,  CHA2DVASc score adjusted) [51]. 
This LA phenotype that was found in patients with an 
undetermined stroke cause supports the hypothesis that 
fibrosis is in the causal pathway of cardioembolic stroke 
independently of AF [51]. Further studies are needed 
to determine the role of anticoagulation in primary and 
secondary stroke prevention in patients with high atrial 
fibrosis.
Women with AF have a higher risk of stroke than men 
who have AF. In a study using CMR, female sex was found 
to be independently associated with left atrial fibrosis, 
after controlling for confounders such as AF and age. More 
studies are needed to understand if this contributes to the 
increased stroke risk related to AF in women compared 
with men [52].
The MESA study aimed to assess the association of 
baseline left atrial phasic function measured with CMR 
in a population free of known cardiovascular disease and 
incident ischemic cerebrovascular events [53]. The authors 
found that reduced total left atrial emptying fraction was 
associated with incident ischemic cerebrovascular events 
independently of known cerebrovascular risk factors and 
incident AF. Assessment of LA function by CMR may, 
therefore, add further information to stratify asymptomatic 
individuals at risk for ischemic stroke.
Silent myocardial infarction
A recent study aimed to investigate if CMR could be use-
ful in identifying unrecognized myocardial infarction (MI) 
and if it was associated with cerebral infarction [54]. It 
used data from a cross-sectional study of ICELAND MI. A 
community-dwelling cohort of Icelandic individuals aged 
67–93 years who underwent brain MRI and LGE CMR 
were enrolled. Unrecognized MI was defined as CMR evi-
dence of MI without a history of clinically evident MI. 
Cerebral infarctions on brain MRI were included regard-
less of associated symptoms. Among 925 participants, 
there were 221 participants (23.9%) with CMR evidence 
of MI, of whom 153 had had an unrecognized MI. There 
were 308 participants (33.3%) with brain MRI evidence 
of cerebral infarction; 93 (10.0%) had embolic infarcts of 
undetermined source. After adjustment for demographic 
factors and vascular risk factors, the odds ratio (OR) 
of having cerebral infarction was 2.0 (95% CI 1.2–3.4; 
p = 0.01) for recognized MI and 1.5 (95% CI 1.02–2.2; 
p = 0.04) for unrecognized MI. Unrecognized MI was also 
associated with embolic infarcts of undetermined source 
(OR 2.0 [95% CI 1.1–3.5]; p = 0.02). These findings sug-
gest that unrecognized MI may be a novel risk factor for 
cardiac embolism and cerebral infarction.
Cardiomyopathies
CMR has diagnostic utility in the assessment of cardio-
myopathies. Cardiomyopathies are rare conditions defined 
by structural and functional abnormalities of the ventric-
ular myocardium that are unexplained by flow-limiting 
coronary artery disease or abnormal loading conditions. 
A recent study was performed to study if CMR could be 
useful in identifying previously undiagnosed cardiomyo-
pathies in a cohort of patients with ischemic stroke who 
had undergone unremarkable standard etiological investi-
gation [55]. One hundred thirty-two patients with a mean 
age of 68.4 years were included. In seven patients (5.3%, 
95% IC 2.59–10.54%), CMR identified a cardiomyopathy. 
Four patients had hypertrophic cardiomyopathy (HCM), two 
had restrictive cardiomyopathy, and one had noncompaction 
cardiomyopathy. Six of these patients had been classified 
as having undetermined stroke and one patient as having 
cardioembolic stroke (AF). A higher frequency of HCM was 
found in the entire cohort and in the undetermined cause 
group compared to the general population (3.03% and 5.81% 
vs 0.2%, respectively, p = 0.001 and p < 0.001). The fre-
quency of noncompaction cardiomyopathy was also higher 
in the cohort (0.76% vs 0.05%, respectively, p < 0.001).
CMR LGE extent (> 14.4%) has been found to be an 
independent predictor for thromboembolic complications 
in patients with HCM [56].
Another study using CMR, evaluated 30 young cryp-
togenic stroke patients and 30 controls to evaluate if non-
compaction cardiomyopathy could be a possible stroke 
cause [57]. In a multivariate conditional logistic regression 
model, the percentage of non-compacted LV volume (odds 
ratio [OR] 1.55, 95% confidence interval [CI] 1.10–2.18, 
p = 0.011) was found to be independently associated with 
cryptogenic ischemic stroke.
Conclusions and future directions
CMR may be useful to clarify established cardioembolic 
stroke causes and to evaluate possible novel mechanisms of 
ischemic stroke (Table 1). Its use should be considered to 
evaluate ischemic stroke patients that are classified as having 
an undetermined stroke etiology after a standard evaluation. 
Atrial fibrosis may play an important role in stroke patho-
physiology. CMR could be useful to phenotype patients with 
atrial fibrosis in clinical trials. Such studies would be useful 
to clarify the best secondary prevention strategies for these 
patients.
In the future, new techniques may simplify and shorten 
the CMR protocol increasing its use and making it more 
widely available. However, because it is not viable in a 
global health care perspective to perform advanced imaging 
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in all patients, the identification of specific patterns (demo-
graphics or imaging) could help to select which patients 
need a more thorough investigation with CMR.
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